Articles tagged with Cancer Patients
A new algorithm, MMRDetect, identifies tumours with mismatch repair deficiencies that can be targeted by immunotherapies. The algorithm uses mutational signatures from genome sequencing data to personalize cancer treatments.
Dr. David Lyden, a Weill Cornell Medicine physician-scientist, has been inducted into the Association of American Physicians for his pioneering work on cancer metastasis and spread. His research reveals that tumors produce factors that prime distant organs to become hospitable sites for cancer growth.
A UT Southwestern Medical Center review of Texas Cancer Registry data found that Black and Hispanic patients under 40 with cancer have lower survival rates compared to their white counterparts. The study also showed that poverty and lack of insurance coverage exacerbate these disparities.
The UVA Center for Engineering in Medicine has developed a robust process to help researchers win funding from institutions like the National Institutes of Health. The center's first seed grant cohorts have achieved astonishing results, including $12 million in follow-on funding with just a $2 million initial investment.
Researchers developed a test using artificial intelligence to measure proteins in advanced bowel cancer patients, predicting treatment benefits. The technique could help doctors and patients decide on the best treatment options, targeting those with higher protein levels.
A new analysis published in Psycho-Oncology found that fear of cancer recurrence leads to increased use of healthcare resources by cancer survivors. Implementing existing effective interventions for fear of cancer recurrence may improve both mental health and reduce unnecessary healthcare usage.
A new Penn State study has found that higher mushroom consumption is associated with a lower risk of cancer. The systematic review and meta-analysis analyzed data from over 19,500 cancer patients and found individuals who ate 18 grams of mushrooms daily had a 45% lower risk of cancer compared to non-mushroom eaters.
A Mayo Clinic study found that 15.5% of patients with colorectal cancer had inherited gene mutations, which can be detected through universal testing and broader gene panels. This discovery has the potential to lead to targeted cancer therapies and earlier disease detection in families.
The Herringbone Microfluidic Probe (HB-MFP) effectively isolates Circulating Tumor Cells from blood samples, providing insights into cancer metastasis. Researchers believe this technology has great promise for diagnosing and prognosticating prostate cancer using liquid biopsies.
City of Hope's Betty Ferrell is honored with the 2021 ONS Lifetime Achievement Award for her decades-long dedication to improving pain management and quality of life for cancer patients. With over $70 million in grant funding, she has trained millions of nurses and clinicians globally on palliative care.
A study published in JAMA Network Open found that treating older patients with early-stage breast cancer did not improve survival rates and may cause harm. Researchers analyzed data from over 3,000 women aged 70 and found that omitting treatments like sentinel lymph node biopsy and radiotherapy did not affect recurrence or survival rates.
The NCCN Foundation has awarded $150,000 in funding to six young investigators advancing research on cancer prevention, racial disparities in screening, and CAR T-cell therapy. The recipients will present their research at the NCCN 2023 Annual Conference.
Researchers have identified specific super-enhancers that stimulate the activity of critical cancer genes in triple-negative breast cancer (TNBC). The study reveals that deleting certain super-enhancers can reduce tumour cell growth and improves survival chances. Dr Rebecca Chin and Dr Wang Xin's findings may lead to the development of...
A new registry study linked non-alcoholic fatty liver (NAFLD) to a 17-fold increased risk of liver cancer, particularly hepatocellular carcinoma. NAFLD patients were also found to have a higher risk of other cancers, emphasizing the need for targeted interventions and personalized screening strategies.
A study of over 1000 patients found UK cancer patients were 1.5 times more likely to die after a COVID-19 diagnosis compared to European counterparts. This increased mortality rate may be attributed to the UK's lagging cancer care and patient frailty.
Researchers at Yale Cancer Center have advanced a tumor-targeting and cell penetrating antibody that can deliver payloads to stimulate an immune response against melanoma. The study achieved almost complete tumor suppression in mice with melanoma tumors following intravenous injection of antibody/RNA complexes.
Researchers at Yale Cancer Center discovered that acquired resistance to immune checkpoint inhibitors is linked to reduced MHC-II molecule expression and increased tumor hypoxia. Combining immune checkpoint inhibitors with anti-hypoxia agents can slow the development of resistance.
A recent study by Yale Cancer Center reveals that young patients with early-onset colorectal cancer (under age 50) have a better survival rate than those diagnosed at older ages. After adjusting for stage at diagnosis, these patients had a 5% lower risk of death compared to those diagnosed between 51-55 years old.
Researchers from MD Anderson Cancer Center present promising results on RET fusion-positive cancers, HGG, LGG, and ovarian cancer. The FDA-approved selpercatinib shows clinical benefits in preventing or inhibiting tumor growth beyond lung and thyroid cancers.
A personalized cancer vaccine developed using a computational platform raised no safety concerns and showed potential benefit in patients with high-risk cancer recurrences. The vaccine was well-tolerated, with minor injection-site reactions, and demonstrated early potential benefits after administration.
A study published in Clinical Cancer Research found that specific gene signatures and immune cells can predict response to immunotherapy in bladder cancer patients. The researchers identified potential biomarkers for treatment resistance and new combination therapeutic approaches to overcome such resistance.
Researchers found that patients with colorectal cancer had a 57-93% decreased risk of death from their cancer depending on the presence and type of mitochondrial DNA mutations. Mitochondrial DNA mutations were present in almost 60% of tumour samples, suggesting potential for improved treatment outcomes.
A newly released position paper from ESMO and SIOPE defines a common vision for improving outcomes for AYAs with cancer in Europe. The paper highlights the key challenges of AYA care, including limited awareness of cancer biology, availability of specialist centres, and access to clinical trials.
The Bertarelli Rare Cancers Fund has awarded over $9 million in grants to nine teams representing 19 lead investigators, advancing research into rare cancers that affect tens of thousands of patients annually. The fund aims to improve detection, diagnosis, treatment, and prevention of rare cancers through multidisciplinary collaborations.
A study published in Radiology found that digital breast tomosynthesis (DBT) reduces the rate of interval cancers, which are more aggressive than screen-detected cancers. The study suggests that DBT may contribute to lower breast cancer mortality by detecting rapidly growing cancers with poorer prognosis.
A collaboration between Michigan State University, Spectrum Health, and Niowave is testing a new radiotherapy approach for bladder cancer. The therapy combines radiotherapy with immunotherapy, which helps the patient's immune system fight off disease, aiming to improve safety and effectiveness.
A collaborative team identified multiple genes with recurrent alterations in uLMS, including HRD, ALT, C-MYC/BET, and PI3K-AKT-mTOR pathway, as potential targets for new treatments.
A new study suggests removing additional tissue around the tumor cavity can reduce positive margins in patients with ductal carcinoma in situ (DCIS) by nearly 65%. Achieving clear margins is crucial in decreasing cancer recurrence, and this technique should be considered for DCIS patients.
A study published in JAMA Network Open found that over 60% of US adults who vape are interested in quitting, with former cigarette smokers having the highest intentions. Despite e-cigarettes being seen as a potential tool for smoking cessation, many users struggle to quit, and current treatments may not be effective for all users.
The study analyzed 412 high-risk NMIBC patients treated with BCG therapy and found significant differences in outcomes according to specific features of the disease. Total median costs at one, two, and five years from start of BCG induction were $29,459, $55,267, and $117,361, respectively.
A cohort study of 672 cancer patients found a cumulative incidence of venous thromboembolism at 12.9% and arterial thromboses at 1.8%. This risk appears to be independent of underlying cancer type or immune checkpoint inhibitor used.
The funding supports development of a new drug testing platform to predict treatment outcomes for patients with cancer. Researchers will leverage tissue bioengineering advances and genomic technologies to reconstruct and grow patient-derived tumor organoids in the presence of different drugs.
Research reveals associations between circulating tumor cell (CTC) mutations and clinical outcomes in metastatic castrate-resistant prostate cancer (mCRPC). The study identified novel genetic alterations linked to response to AR inhibitors, including gains of ATM, NCOR2, and HSD17B4, which were associated with sensitivity to treatment.
A new study reveals that patients with newly diagnosed incurable cancer experience significant physical and emotional distress, including anxiety and depression. Comprehensive palliative care services are essential to address these needs and improve quality of life for patients.
The conference explored updates to NCCN Clinical Practice Guidelines, new research, and strategies for preventing HPV-associated cancers. Experts discussed ways to improve racial equity in cancer care, including reducing disparities and promoting guideline-adherent care.
A team at Washington University in St. Louis has developed an imaging technique using acoustic resolution photoacoustic microscopy co-registered with ultrasound and paired with deep learning to differentiate between residual tumors and healthy tissue in rectal cancer patients after chemotherapy and radiation. This technique shows promi...
Scientists genetically engineered myeloid cells to deliver an anticancer signal, shrinking tumors and preventing cancer from spreading to other parts of the body. The study shows promise as a potential treatment for metastatic cancer, with treated mice living substantially longer and experiencing reduced metastatic cancer.
A clinical trial tested a mutation-specific vaccine against IDH1-mutated gliomas, a type of diffuse brain tumor. The vaccine proved safe and triggered the desired immune response in 93% of patients, with some experiencing pseudoprogression and tumor growth slowing.
Researchers at Kumamoto University found that aging cells in abdominal fluid contribute to peritoneal dissemination of gastric cancer by promoting cellular senescence and inflammation. This understanding could lead to new treatments targeting cancer cells and associated fibroblasts.
The CCC19 study found associations between laboratory measures, clinical factors, and poor clinical outcomes in patients with cancer diagnosed with SARS-CoV-2 infection. Patients with COVID-19 and cancer had a higher risk of hospitalization and death compared to the general population.
A new study found that most people with cancer produce antibodies at a rate comparable to the general population, suggesting they should respond well to COVID-19 vaccines. However, patients with blood cancers had a lower seroconversion rate due to immunosuppressive treatments.
A new technique for sampling and testing cells from Barrett's esophagus patients can detect specific chromosomal alterations, including the presence of esophageal adenocarcinoma. The approach combines esophageal brushing with massively parallel sequencing to provide an accurate assessment of disease stages and identify high-risk patients.
Researchers at Vall d'Hebron Institute of Oncology are conducting a first-in-human Phase I trial to evaluate the safety and efficacy of Peptomyc's novel Myc inhibitor Omomyc in treating advanced solid tumors. The trial aims to confirm the compound's therapeutic potential, particularly for patients with progressed disease.
A cancer oncologist reflects on advising patients with cancer about travel during the pandemic. The author considers the importance of weighing the potential benefits of travel against the increased risk of complications.
A recent SWOG Cancer Research Network study found that even with access to clinical trials, cancer patients living in the poorest neighborhoods have a nearly 30% greater chance of dying from their disease. The disparity persists despite uniform high-quality care.
A study reveals that over one in ten lung cancer patients are unsure of their tumor type, highlighting the need for improved communication between patients and healthcare providers. Language differences and complex treatments contribute to these misunderstandings, jeopardizing patient care.
A new study found that cancer survivors have a significantly higher risk of cardiovascular disease in the next decade. Researchers estimate that about 8% of cancer survivors will develop heart disease or stroke over the 10-year period, compared to 5% of those without a cancer history.
A minimally invasive treatment known as radiofrequency ablation (RFA) provides quick and sustained pain relief, improving quality of life for cancer patients with bone tumors. The benefits last more than 12 months, significantly outperforming radiation treatment.
Scientists detected novel pathogens in colorectal cancer patients near tumors, triggering chronic inflammation that promotes cancer development. BMMFs were more frequently found near malignant tumors than healthy tissue.
Researchers analyzed sociodemographic and hospital characteristics of patients undergoing cancer surgery before and during the pandemic. The study found significant differences in these factors among patients with varying levels of access to care.
Researchers conducted a randomized intervention that improved continuity of care and interprofessional collaboration between lung cancer patients and their family physicians. The bidirectional exchange of patient information and care summaries led to enhanced patient and family physician perceptions of care, resulting in better outcomes.
A new study found that global clinical trials enrolled less than half the proportion of Black patients as U.S. trials, highlighting a trend that may exacerbate racial disparities in cancer research and care. The study suggests that globalization of cancer clinical trials may be a key driver of these disparities.
Researchers at Yale University have developed a model where human red blood cells are rescued in circulation using combined liver and growth factor humanization. This breakthrough has the potential to treat diseases such as myelodysplastic syndrome, sickle cell disease, and malaria.
A new study found that cancer survivors who walked at a slow pace had a significantly increased risk of death from any cause, with the association holding for nine cancer types. The researchers call for more research into targeted interventions to improve walking ability and increase survival among cancer patients.
Researchers used induced pluripotent stem cells to identify correlations between genetic variants and altered expression patterns in human cells. The study found thousands of disease-associated genetic variants linked to specific diseases, including coronary heart disease and hereditary cancers.
Researchers at Harvard Medical School and Dana-Farber Cancer Institute found that cancer-causing mutations can arise decades ago, in some cases as far back as 40 years before diagnosis. The study used genetic sequencing and phylogenetic analysis to reconstruct the lineage history of cancer cells in two patients with a rare blood cancer.
A new study found that cancer patients who died by suicide were generally older and less likely to have histories of physical and psychiatric problems. These patients were also more likely to communicate about their suicidal intent before death.
Utah researchers identify mutation hotspots and find that approximately 2% of healthy participants had the same mutations as cancer patients. This study provides new insights into the development of blood cancers and may help identify people at risk.
A global survey found that COVID-19 had a significant impact on childhood cancer care, with 78% of hospitals reporting disruptions. Disruptions included reduced clinical staff, unavailable chemotherapy and radiotherapy, and treatment abandonment.
Advanced liver fibrosis worsens cancer-specific and overall survival in iCCA patients, regardless of surgical resection. Patients with advanced fibrosis are at increased risk of mortality across follow-up periods.